Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity. As patients age on therapy for their chronic lymphocytic leukemia (CLL), ...
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...
During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous ...
Two years after premiering a 13-minute documentary about three eczema patients, Abbvie has again teamed with branded entertainment firm Passion Point Collective, this time for a 16-minute documentary ...
Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...
Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results